de Veer S - Search Results

1

Olmsted syndrome with erythromelalgia caused by recessive transient receptor potential vanilloid 3 mutations.

Duchatelet S, Guibbal L, de Veer S, Fraitag S, Nitschké P, Zarhrate M, Bodemer C, Hovnanian A. Duchatelet S, et al. Among authors: de veer s. Br J Dermatol. 2014 Sep;171(3):675-8. doi: 10.1111/bjd.12951. Epub 2014 Aug 4. Br J Dermatol. 2014. PMID: 24606194 No abstract available.

2

A new TRPV3 missense mutation in a patient with Olmsted syndrome and erythromelalgia.

Duchatelet S, Pruvost S, de Veer S, Fraitag S, Nitschké P, Bole-Feysot C, Bodemer C, Hovnanian A. Duchatelet S, et al. Among authors: de veer s. JAMA Dermatol. 2014 Mar;150(3):303-6. doi: 10.1001/jamadermatol.2013.8709. JAMA Dermatol. 2014. PMID: 24452206 Free article. Review.

3

Proteases and proteomics: cutting to the core of human skin pathologies.

de Veer SJ, Furio L, Harris JM, Hovnanian A. de Veer SJ, et al. Proteomics Clin Appl. 2014 Jun;8(5-6):389-402. doi: 10.1002/prca.201300081. Epub 2014 Apr 13. Proteomics Clin Appl. 2014. PMID: 24677727 Review.

4

Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.

de Veer SJ, Furio L, Swedberg JE, Munro CA, Brattsand M, Clements JA, Hovnanian A, Harris JM. de Veer SJ, et al. J Invest Dermatol. 2017 Feb;137(2):430-439. doi: 10.1016/j.jid.2016.09.017. Epub 2016 Sep 30. J Invest Dermatol. 2017. PMID: 27697464 Free article.

5

Proteases: common culprits in human skin disorders.

de Veer SJ, Furio L, Harris JM, Hovnanian A. de Veer SJ, et al. Trends Mol Med. 2014 Mar;20(3):166-78. doi: 10.1016/j.molmed.2013.11.005. Epub 2013 Dec 28. Trends Mol Med. 2014. PMID: 24380647 Review.

6

Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.

Furio L, de Veer S, Jaillet M, Briot A, Robin A, Deraison C, Hovnanian A. Furio L, et al. Among authors: de veer s. J Exp Med. 2014 Mar 10;211(3):499-513. doi: 10.1084/jem.20131797. Epub 2014 Feb 17. J Exp Med. 2014. PMID: 24534191 Free PMC article.

7

Design of Potent and Selective Cathepsin G Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold.

Swedberg JE, Li CY, de Veer SJ, Wang CK, Craik DJ. Swedberg JE, et al. J Med Chem. 2017 Jan 26;60(2):658-667. doi: 10.1021/acs.jmedchem.6b01509. Epub 2017 Jan 18. J Med Chem. 2017. PMID: 28045523

8

Engineering potent mesotrypsin inhibitors based on the plant-derived cyclic peptide, sunflower trypsin inhibitor-1.

de Veer SJ, Li CY, Swedberg JE, Schroeder CI, Craik DJ. de Veer SJ, et al. Eur J Med Chem. 2018 Jul 15;155:695-704. doi: 10.1016/j.ejmech.2018.06.029. Epub 2018 Jun 21. Eur J Med Chem. 2018. PMID: 29936356

9

Characterising the Subsite Specificity of Urokinase-Type Plasminogen Activator and Tissue-Type Plasminogen Activator using a Sequence-Defined Peptide Aldehyde Library.

Li CY, de Veer SJ, Law RHP, Whisstock JC, Craik DJ, Swedberg JE. Li CY, et al. Chembiochem. 2019 Jan 2;20(1):46-50. doi: 10.1002/cbic.201800395. Epub 2018 Oct 24. Chembiochem. 2019. PMID: 30225958

10

Binding Loop Substitutions in the Cyclic Peptide SFTI-1 Generate Potent and Selective Chymase Inhibitors.

Li CY, Yap K, Swedberg JE, Craik DJ, de Veer SJ. Li CY, et al. J Med Chem. 2020 Jan 23;63(2):816-826. doi: 10.1021/acs.jmedchem.9b01811. Epub 2020 Jan 9. J Med Chem. 2020. PMID: 31855419

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters